Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01674842 · ClinicalTrials.gov registry record · Phase 1
Cisplatin + RT for Triple Negative Breast Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT01674842 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 55 participants.
The verdict
NCT01674842, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have undergone breast-conserving surgery or mastectomy. Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of cisplatin when given concurrently with radiation therapy for participants with Stage II or III breast cancer who have undergone breast conserving surgery or mastectomy
Interventions
- DRUG Cisplatin
- RADIATION Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2012-10 |
| Est. Completion | 2021-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01674842
The ClinicalTrials.gov registry entry for NCT01674842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cisplatin is the first listed.
NCT01674842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01674842 about?
NCT01674842 is a clinical study titled "Cisplatin + RT for Triple Negative Breast Cancer". This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have undergone breast-conserving surgery or mastectomy. Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD)...
What is the current status of trial NCT01674842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2012-10. Estimated completion is 2021-06-08.
What interventions are being tested in trial NCT01674842?
The interventions under investigation include: Cisplatin (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01674842?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.